Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification.